@article{18307,
  abstract     = {Vaccination is the most effective tool to control infectious diseases. However, the evolution of vaccine resistance, exemplified by vaccine resistance in SARS-CoV-2, remains a concern. Here, we model complex vaccination strategies against a pathogen with multiple epitopes—molecules targeted by the vaccine. We found that a vaccine targeting one epitope was ineffective in preventing vaccine escape. Vaccine resistance in highly infectious pathogens was prevented by the full-epitope vaccine, that is, one targeting all available epitopes, but only when the rate of pathogen evolution was low. Strikingly, a bet-hedging strategy of random administration of vaccines targeting different epitopes was the most effective in preventing vaccine resistance in pathogens with the low rate of infection and high rate of evolution. Thus, complex vaccination strategies, when biologically feasible, may be preferable to the currently used single-vaccine approaches for long-term control of disease outbreaks, especially when applied to livestock with near 100% vaccination rates.},
  author       = {Rella, Simon and Kulikova, Yuliya A. and Minnegalieva, Aygul and Kondrashov, Fyodor},
  issn         = {1558-5646},
  journal      = {Evolution: International journal of organic evolution},
  number       = {10},
  pages        = {1722--1738},
  publisher    = {Oxford University Press},
  title        = {{Complex vaccination strategies prevent the emergence of vaccine resistance}},
  doi          = {10.1093/evolut/qpae106},
  volume       = {78},
  year         = {2024},
}

@inproceedings{14862,
  author       = {Rella, Simon and Kulikova, Y and Minnegalieva, Aygul and Kondrashov, Fyodor},
  booktitle    = {European Journal of Public Health},
  issn         = {1464-360X},
  keywords     = {Public Health, Environmental and Occupational Health},
  number       = {Supplement_2},
  publisher    = {Oxford University Press},
  title        = {{Complex vaccination strategies prevent the emergence of vaccine resistance}},
  doi          = {10.1093/eurpub/ckad160.597},
  volume       = {33},
  year         = {2023},
}

@article{12131,
  abstract     = {Replication-incompetent adenoviral vectors have been extensively used as a platform for vaccine design, with at least four anti-COVID-19 vaccines authorized to date. These vaccines elicit neutralizing antibody responses directed against SARS-CoV-2 Spike protein and confer significant level of protection against SARS-CoV-2 infection. Immunization with adenovirus-vectored vaccines is known to be accompanied by the production of anti-vector antibodies, which may translate into reduced efficacy of booster or repeated rounds of revaccination. Here, we used blood samples from patients who received an adenovirus-based Gam-COVID-Vac vaccine to address the question of whether anti-vector antibodies may influence the magnitude of SARS-CoV-2-specific humoral response after booster vaccination. We observed that rAd26-based prime vaccination with Gam-COVID-Vac induced the development of Ad26-neutralizing antibodies, which persisted in circulation for at least 9 months. Our analysis further indicates that high pre-boost Ad26 neutralizing antibody titers do not appear to affect the humoral immunogenicity of the Gam-COVID-Vac boost. The titers of anti-SARS-CoV-2 RBD IgGs and antibodies, which neutralized both the wild type and the circulating variants of concern of SARS-CoV-2 such as Delta and Omicron, were independent of the pre-boost levels of Ad26-neutralizing antibodies. Thus, our results support the development of repeated immunization schedule with adenovirus-based COVID-19 vaccines.},
  author       = {Byazrova, Maria G. and Astakhova, Ekaterina A. and Minnegalieva, Aygul and Sukhova, Maria M. and Mikhailov, Artem A. and Prilipov, Alexey G. and Gorchakov, Andrey A. and Filatov, Alexander V.},
  issn         = {2059-0105},
  journal      = {npj Vaccines},
  keywords     = {Pharmacology (medical), Infectious Diseases, Pharmacology, Immunology, SARS-COV-2, COVID},
  publisher    = {Springer Nature},
  title        = {{Anti-Ad26 humoral immunity does not compromise SARS-COV-2 neutralizing antibody responses following Gam-COVID-Vac booster vaccination}},
  doi          = {10.1038/s41541-022-00566-x},
  volume       = {7},
  year         = {2022},
}